Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 48 percent increase over losses of $(0.25) per share from the same period last year. The company reported $258.000 thousand in sales this quarter. This is a 95.61 percent decrease over sales of $5.874 million the same period last year.